<DOC>
	<DOCNO>NCT02844517</DOCNO>
	<brief_summary>The objective study clinical staff gain experience use propose artificial pancreas system name inControl inControl Cloud assess 24/7 in-home usability prior initiate large randomize controlled trial .</brief_summary>
	<brief_title>International Diabetes Closed Loop ( iDCL ) Trial : Research Site Training Protocol</brief_title>
	<detailed_description>Participation study require 5 study visit 2-4 week . - Visit 1 : screening/enrollment visit ass study eligibility . - Visit 2 : continuous glucose monitor ( CGM ) train initiation session base upon current prior use CGM ; subject n't currently use CGM , subject train may ask wear CGM home 1 week . - Visit 3 : subject taught use study insulin pump . - Visit 4 : subject train use inControl wear home 14 day . - Visit 5 : subject return study equipment complete questionnaire .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Inclusion Criteria 1 . Clinical diagnosis , base investigator assessment , type 1 diabetes least one year use insulin least 1 year 2 . Use insulin pump least 6 month establish parameter basal rate ( ) , carbohydrate ratio ( ) insulin sensitivity factor ( ) least 3 month . 3 . Age 14.0 &lt; 75.0 year 4 . HbA1c level &lt; 10.5 % screen 5 . For female , currently know pregnant . If female sexually active , must agree use form contraception prevent pregnancy participant study . A negative serum urine pregnancy test require premenopausal woman surgically sterile . Subjects become pregnant discontinue study . Also , subject study develop express intention become pregnant within timespan study discontinue . 6 . Have care partner commit participate training activity , knowledgeable time participant location , present available provide assistance system use night 7 . Willingness , use closedloop system , stop closedloop take acetaminophen avoid closedloop least 4 hour afterward 8 . Willingness suspend use personal CGM duration clinical trial study CGM use 9 . Willingness establish network connectivity daily basis either via local WiFi network via studyprovided cellular service 10 . Investigator confidence subject successfully operate study device capable adhere protocol 11 . Currently use insulin one follow rapidacting insulin time enrollment : insulin lispro ( Humalog ) , insulin aspart ( Novolog ) , insulin glulisine ( Apidra ) Exclusion Criteria 1 . More one episode diabetic ketoacidosis ( DKA ) 6 month prior enrollment 2 . More one episode severe hypoglycemia involve seizure loss consciousness 6 month prior enrollment 3 . Medical need chronic acetaminophen 4 . Concurrent use noninsulin glucoselowering agent ( include GLP1 agonist , Symlin , DPP4 inhibitor , SGLT2 inhibitor , biguanides , sulfonylureas naturaceuticals ) . 5 . Hemophilia bleed disorder 6 . A condition , opinion investigator designee , would put participant study risk 7 . Participation another pharmaceutical device trial time enrollment study 8 . Employed , immediate family member employ TypeZero Technologies , LLC</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Artificial Pancreas</keyword>
	<keyword>Closed Loop Control</keyword>
	<keyword>Continuous Glucose Monitor ( CGM )</keyword>
</DOC>